Table 1.
Baseline information of Survivor group and Non-survivor group.
| Survivor group (n = 254) | Non-survivor group (n = 95) | P value | |
|---|---|---|---|
| Patient characteristics | |||
| Sex, female, N (%) | 93 (26.3%) | 38 (40.0%) | 0.561 |
| Age, median (interquartile ranges) | 76 (67, 85) | 77 (70, 84) | 0.474 |
| BMI (Mean ± SD) | 21.9 ± 3.0 | 21.2 ± 3.2 | 0.077 |
| Comorbidities, N (%) | |||
| Hypertension | 143 (56.3%) | 52 (54.7%) | 0.794 |
| Diabetes | 79 (31.1%) | 34 (35.8%) | 0.405 |
| Heart disease | 81 (31.9%) | 35 (36.8%) | 0.382 |
| Chronic pulmonary disease | 35 (13.8%) | 9 (9.5%) | 0.281 |
| Cerebrovascular disease | 46 (18.1%) | 14 (14.7%) | 0.457 |
| Chronic mild or severe liver disease | 11 (4.3%) | 5 (5.3%) | 0.711 |
| Chronic kidney disease | 19 (7.5%) | 11 (11.6%) | 0.224 |
| Vital signs (Mean ± SD) | |||
| HR | 88.9 ± 22.0 | 91.5 ± 18.9 | 0.310 |
| SBP | 124.1 ± 21.1 | 123.9 ± 25.6 | 0.929 |
| T | 36.9 ± 0.7 | 37.0 ± 0.7 | 0.421 |
| Infection site, N (%) | |||
| Lung | 191 (75.2%) | 76 (80.0%) | 0.346 |
| Abdomen | 41 (16.1%) | 9 (9.5%) | 0.114 |
| Others | 22 (8.7%) | 10 (10.5%) | 0.591 |
| Laboratory parameters (Mean ± SD) | |||
| WBC ( × 109/L) | 12.3 ± 11.1 | 12.6 ± 5.9 | 0.817 |
| PLT ( × 109/L) | 172.4 ± 91.5 | 196.6 ± 110.6 | 0.039 |
| ALT (U/L) | 61.1 ± 170.7 | 72.8 ± 177.5 | 0.572 |
| TBIL (μmol/L) | 23.2 ± 26.4 | 25.5 ± 36.8 | 0.518 |
| Scr (μmol/L) | 122.5 ± 305.2 | 138.4 ± 122.4 | 0.622 |
| SII (Mean ± SD) | 1.7 ± 2.3 | 7.1 ± 13.2 | <0.0001 |
| Score system (interquartile ranges) | |||
| SIRI | 2 (2, 3) | 2 (2, 3) | 0.208 |
| APACHE II | 13 (9, 19) | 18 (13, 22) | <0.0001 |
| SOFA | 5 (3, 6) | 6 (4, 9) | <0.0001 |
| qSOFA | 1 (1, 1) | 2 (1, 2) | <0.0001 |
Abbreviations: BMI, Body Mass Index; SD, Standard deviation; HR, Heart rate; SBP, Systolic blood pressure; T, Temperature; WBC, White blood cell; PLT, Platelet; ALT, Alanine aminotransferase; TBIL, Total bilirubin; Scr, Serum creatinine; SII, Systemic Immune-Inflammation Index.